Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice

Abstract Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment of a range of diseases or medical conditions. Autologous or allogeneic MSCs obtained from self or donors have their own advantages and disadvantages in their medical practice. Therapeutic benefits of u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chenghai Li, Hua Zhao, Linna Cheng, Bin Wang
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Mesenchymal stem/stromal cell Single-nucleotide polymorphism Stem cell heterogeneity Stem cell microenvironment Stem cell transplantation Biotechnology TP248.13-248.65 Biology (General) QH301-705.5 Biochemistry QD415-436
Acceso en línea:	https://doaj.org/article/b9a0181604a0473094a7f3f403ffd713
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9a0181604a0473094a7f3f403ffd713
record_format	dspace
spelling	oai:doaj.org-article:b9a0181604a0473094a7f3f403ffd7132021-11-08T11:03:37ZAllogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice10.1186/s13578-021-00698-y2045-3701https://doaj.org/article/b9a0181604a0473094a7f3f403ffd7132021-11-01T00:00:00Zhttps://doi.org/10.1186/s13578-021-00698-yhttps://doaj.org/toc/2045-3701Abstract Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment of a range of diseases or medical conditions. Autologous or allogeneic MSCs obtained from self or donors have their own advantages and disadvantages in their medical practice. Therapeutic benefits of using autologous vs. allogeneic MSCs are inconclusive. Transplanted MSCs within the body interact with their physical microenvironment or niche, physiologically or pathologically, and such cells in a newly established tissue microenvironment may be impacted by the pathological harmful environmental factors to alter their unique biological behaviors. Meanwhile, a temporary microenvironment/niche may be also altered by the resident or niche-surrounding MSCs. Therefore, the functional plasticity and heterogeneity of MSCs caused by different donors and subpopulations of MSCs may result in potential uncertainty in their safe and efficacious medical practice. Acknowledging a connection between MSCs’ biology and their existing microenvironment, donor-controlled clinical practice for the long-term therapeutic benefit is suggested to further consider minimizing MSCs potential harm for MSC-based individual therapies. In this review, we summarize the advantages and disadvantages of autologous vs. allogeneic MSCs in their therapeutic applications. Among other issues, we highlight the importance of better understanding of the various microenvironments that may affect the properties of niche-surrounding MSCs and discuss the clinical applications of MSCs within different contexts for treatment of different diseases including cardiomyopathy, lupus and lupus nephritis, diabetes and diabetic complications, bone and cartilage repair, cancer and tissue fibrosis.Chenghai LiHua ZhaoLinna ChengBin WangBMCarticleMesenchymal stem/stromal cellSingle-nucleotide polymorphismStem cell heterogeneityStem cell microenvironmentStem cell transplantationBiotechnologyTP248.13-248.65Biology (General)QH301-705.5BiochemistryQD415-436ENCell & Bioscience, Vol 11, Iss 1, Pp 1-21 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Mesenchymal stem/stromal cell Single-nucleotide polymorphism Stem cell heterogeneity Stem cell microenvironment Stem cell transplantation Biotechnology TP248.13-248.65 Biology (General) QH301-705.5 Biochemistry QD415-436
spellingShingle	Mesenchymal stem/stromal cell Single-nucleotide polymorphism Stem cell heterogeneity Stem cell microenvironment Stem cell transplantation Biotechnology TP248.13-248.65 Biology (General) QH301-705.5 Biochemistry QD415-436 Chenghai Li Hua Zhao Linna Cheng Bin Wang Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
description	Abstract Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment of a range of diseases or medical conditions. Autologous or allogeneic MSCs obtained from self or donors have their own advantages and disadvantages in their medical practice. Therapeutic benefits of using autologous vs. allogeneic MSCs are inconclusive. Transplanted MSCs within the body interact with their physical microenvironment or niche, physiologically or pathologically, and such cells in a newly established tissue microenvironment may be impacted by the pathological harmful environmental factors to alter their unique biological behaviors. Meanwhile, a temporary microenvironment/niche may be also altered by the resident or niche-surrounding MSCs. Therefore, the functional plasticity and heterogeneity of MSCs caused by different donors and subpopulations of MSCs may result in potential uncertainty in their safe and efficacious medical practice. Acknowledging a connection between MSCs’ biology and their existing microenvironment, donor-controlled clinical practice for the long-term therapeutic benefit is suggested to further consider minimizing MSCs potential harm for MSC-based individual therapies. In this review, we summarize the advantages and disadvantages of autologous vs. allogeneic MSCs in their therapeutic applications. Among other issues, we highlight the importance of better understanding of the various microenvironments that may affect the properties of niche-surrounding MSCs and discuss the clinical applications of MSCs within different contexts for treatment of different diseases including cardiomyopathy, lupus and lupus nephritis, diabetes and diabetic complications, bone and cartilage repair, cancer and tissue fibrosis.
format	article
author	Chenghai Li Hua Zhao Linna Cheng Bin Wang
author_facet	Chenghai Li Hua Zhao Linna Cheng Bin Wang
author_sort	Chenghai Li
title	Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
title_short	Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
title_full	Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
title_fullStr	Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
title_full_unstemmed	Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
title_sort	allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
publisher	BMC
publishDate	2021
url	https://doaj.org/article/b9a0181604a0473094a7f3f403ffd713
work_keys_str_mv	AT chenghaili allogeneicvsautologousmesenchymalstemstromalcellsintheirmedicationpractice AT huazhao allogeneicvsautologousmesenchymalstemstromalcellsintheirmedicationpractice AT linnacheng allogeneicvsautologousmesenchymalstemstromalcellsintheirmedicationpractice AT binwang allogeneicvsautologousmesenchymalstemstromalcellsintheirmedicationpractice
_version_	1718442464278216704

Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice

Ejemplares similares